Menu Search
Equities

Personalis Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
04X:DUS

Personalis Inc

Actions
  • Price (EUR)6.78
  • Today's Change0.275 / 4.23%
  • Shares traded--
  • 1 Year change+34.96%
  • Beta2.0669
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

  • Revenue in USD (TTM)69.10m
  • Net income in USD-73.88m
  • Incorporated2011
  • Employees229.00
  • Location
    Personalis Inc6600 Dumbarton CircleFREMONT 94555United StatesUSA
  • Phone+1 (650) 752-1300
  • Fax+1 (302) 531-3150
  • Websitehttps://www.personalis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.